Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Avacta Group plc ( (GB:AVCT) ) has issued an announcement.
Avacta Group plc announced preliminary clinical data from its Phase 1b trial of Faridoxorubicin in patients with salivary gland cancer, with detailed results to be presented on December 17, 2025. This announcement marks a significant step in Avacta’s efforts to advance its PDC technology, potentially improving treatment outcomes and positioning the company as a leader in targeted cancer therapies.
The most recent analyst rating on (GB:AVCT) stock is a Hold with a £81.00 price target. To see the full list of analyst forecasts on Avacta Group plc stock, see the GB:AVCT Stock Forecast page.
Spark’s Take on GB:AVCT Stock
According to Spark, TipRanks’ AI Analyst, GB:AVCT is a Neutral.
Avacta Group plc’s overall stock score is driven by significant financial challenges and valuation concerns, despite positive technical indicators and promising corporate developments. The company’s reliance on external financing and lack of profitability weigh heavily on its score.
To see Spark’s full report on GB:AVCT stock, click here.
More about Avacta Group plc
Avacta Group plc is a clinical stage life sciences company focused on developing innovative drug delivery systems, specifically peptide drug conjugates (PDC) through its proprietary pre|CISION® platform. This technology aims to enhance oncology drug efficacy by targeting tumor sites directly, thereby reducing toxicity and side effects for patients.
Average Trading Volume: 2,620,554
Technical Sentiment Signal: Hold
Current Market Cap: £342.4M
See more data about AVCT stock on TipRanks’ Stock Analysis page.